Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Takeda
Columbia University
University of California, San Diego
USWM, LLC (dba US WorldMeds)
Case Comprehensive Cancer Center
NeoImmuneTech
Hoffmann-La Roche
Institut Bergonié
University of Texas Southwestern Medical Center
AstraZeneca
Pfizer
Wake Forest University Health Sciences
University of Ulm
Dana-Farber Cancer Institute
Bristol-Myers Squibb
Cedars-Sinai Medical Center
Grupo Espanol de Tumores Neuroendocrinos
University Hospital, Akershus
Astellas Pharma Inc
University of California, San Diego
Astellas Pharma Inc
University of Maryland, Baltimore
Transgene
St. Jude Children's Research Hospital
Dartmouth-Hitchcock Medical Center
EMD Serono
University of Wisconsin, Madison
Teva Branded Pharmaceutical Products R&D, Inc.
Cytovation AS
Vanderbilt University Medical Center
Boehringer Ingelheim
Boehringer Ingelheim
University of Kentucky
GlaxoSmithKline
George Washington University
University of Pittsburgh
AbbVie
GlaxoSmithKline
St. Jude Children's Research Hospital
Eli Lilly and Company
Revolution Medicines, Inc.
Pfizer
Werewolf Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Abramson Cancer Center at Penn Medicine
Eli Lilly and Company
UNC Lineberger Comprehensive Cancer Center
EMD Serono